Omega-3 EPA vs DHA

Supplement Science Editorial Team·Evidence-Based Supplement Research

Published Apr 1, 2026

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

EPA is better for inflammation and mood support, while DHA is essential for brain structure and eye health.

Head-to-Head Comparison

Criteria	Omega-3 EPA	DHA	Winner
Bioavailability	High — well absorbed from fish oil and algal sources	High — well absorbed, preferentially incorporated into cell membranes	Tie
Clinical Evidence	Strong — cardiovascular, anti-inflammatory, mood	Strong — brain development, cognitive, retinal health	Tie
GI Tolerability	Good — mild fishy aftertaste possible	Good — mild fishy aftertaste possible	Tie
Cost	$0.15-0.35/serving (EPA-dominant formulas)	$0.20-0.45/serving (DHA-dominant or algal)	Omega-3 EPA
Mental Health & Mood Support	Strong — meta-analyses favor EPA for depression	Moderate — structural role but weaker for mood outcomes	Omega-3 EPA

Detailed Analysis

Bioavailability

Both EPA and DHA are well absorbed from triglyceride and phospholipid forms, especially when taken with a fat-containing meal. Neither has a clear absorption advantage over the other.

Clinical Evidence

Both have extensive clinical evidence, but in different domains. EPA dominates cardiovascular and anti-inflammatory research (e.g., REDUCE-IT trial), while DHA has stronger evidence for neurodevelopment and structural brain health.

GI Tolerability

Both EPA and DHA have similar GI tolerability profiles. Fishy burps and mild nausea are dose-dependent and relate more to the supplement form (ethyl ester vs triglyceride) than the specific fatty acid.

Cost

EPA-dominant fish oil supplements tend to be slightly cheaper because EPA is more abundant in common fish oil sources. DHA-dominant and algal DHA products carry a modest premium.

Mental Health & Mood Support

Multiple meta-analyses show EPA at doses of 1-2g/day significantly improves depressive symptoms, outperforming DHA in head-to-head mood trials. EPA's anti-inflammatory mechanism is thought to underlie its antidepressant effect.

Our Verdict

Neither universally wins — EPA excels for inflammation and depression, DHA for brain structure and pregnancy. Most people should take both; bias toward EPA for mood, DHA for cognition.

Which Omega-3 Form Is Right for You?

Answer below to get a personalized recommendation.

What matters most to you?

Learn more about

Omega-3

Frequently Asked Questions

Can I take EPA and DHA together?

Yes, and most experts recommend it. Standard fish oil naturally contains both EPA and DHA. They have complementary mechanisms: EPA reduces inflammatory signaling while DHA maintains cell membrane fluidity in the brain and retina. A combined supplement with at least 500mg EPA+DHA daily covers most health goals.

Which is better for depression and anxiety?

EPA is the stronger choice for depression. A 2019 meta-analysis in Translational Psychiatry found that supplements with 60% or more EPA showed significant antidepressant effects, while DHA-dominant formulas did not. For depression support, look for at least 1,000mg EPA per day.

Is a DHA-dominant supplement worth the extra cost?

It depends on your goals. DHA-dominant supplements are worth the premium during pregnancy (fetal brain development requires DHA), for cognitive support in older adults, and for eye health. For general cardiovascular and anti-inflammatory benefits, a standard EPA-dominant fish oil is more cost-effective.

How much EPA and DHA should I take daily?

General health: 500-1,000mg combined EPA+DHA. For depression: 1,000-2,000mg EPA. For cardiovascular risk: 2,000-4,000mg EPA (per REDUCE-IT trial). For pregnancy: at least 200-300mg DHA. Always take with a meal containing fat for optimal absorption.

References

Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, Fan B, Lu C, McIntyre RS (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry. DOI PubMed
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine. DOI PubMed